Healthcare VC Firms: Strategies, Trends, and Key Players

Curious about who’s funding the next wave of health care innovation? This article breaks down the leading health care VC firms, what they focus on, and how they shape the future of the industry.

Whether you’re exploring investment opportunities, building a startup, or researching the space, you’ll find a clear look at the firms making the biggest impact.

Top Healthcare Venture Capital Firms and Their Global Presence

Healthcare venture capital firms play a central role in funding innovation, bringing breakthrough treatments, medical devices, and digital health solutions to life. Some firms stand out not just for the capital they deploy, but for their influence, networks, and consistent track record in identifying high-potential healthcare companies.

As Risetku noted, “Healthcare’s share of global VC deal activity is expected to hold steady at 16.5% in 2025, with robust deal activity driven by both strategic acquisitions and financial investments.”

Below is an overview of the most prominent healthcare VC firms, including their geographic footprint, focus areas, and what sets them apart in the industry.

OrbiMed (New York, USA)

OrbiMed is widely recognized as one of the largest and most influential healthcare-focused VC firms. With offices in New York, San Francisco, London, Shanghai, and Mumbai, OrbiMed has a truly global reach.

The firm invests across the entire healthcare spectrum—from biotech and pharmaceuticals to medical devices and diagnostics. Its global presence allows it to source deals in both established and emerging markets – a pattern I’ve observed firsthand through years of working with venture firms.

Andreessen Horowitz (California, USA)

Though better known for its dominance in tech, Andreessen Horowitz (a16z) has become a major player in healthtech. Based in Silicon Valley, the firm manages a dedicated bio fund that targets digital health, AI in life sciences, and personalized medicine.

Its U.S. location positions it well within the heart of health innovation ecosystems (something I’ve seen repeatedly while investing across multiple Y Combinator batches), including partnerships with academic centers and startups in the Bay Area.

Optum Ventures (Boston, USA)

Optum Ventures, the venture arm of UnitedHealth Group, focuses specifically on digital health, healthcare services, and data-driven care models. Headquartered in Boston, with offices in Minneapolis and London, the firm has a unique advantage in integrating its investments with broader healthcare delivery networks.

Its close relationship with a major payer-provider gives it strategic insight into scalable healthcare models – a factor I came to deeply appreciate during my time as a Financial Policy Advisor.

Versant Ventures (California, USA and Toronto, Canada)

Versant Ventures specializes in biotech venture capital and life sciences, with offices across North America and Europe. It is known for its cross-border investment model and for creating “discovery engines” — in-house incubators that build companies from early-stage research.

The firm’s strong presence in California and Toronto gives it access to both U.S. and Canadian research institutions.

New Enterprise Associates (NEA) (Maryland, USA)

NEA is one of the largest VC firms in the world and has a long-standing commitment to healthcare. While it invests across sectors, its healthcare portfolio is substantial, spanning medical devices, biotech, and healthcare IT.

With its size and reach, NEA often leads larger rounds and supports companies across multiple growth stages.

Deerfield Management (New York, USA)

Deerfield is both a VC and asset management firm focused exclusively on healthcare. It is deeply involved in funding drug discovery, therapeutics, and healthcare services.

Based in New York, it also runs the Deerfield Institute, which supports research and analytics to guide its investments. Its East Coast location provides access to top medical research institutions.

Khosla Ventures (California, USA)

Khosla Ventures, headquartered in Menlo Park, invests heavily in digital health, health data, and AI-driven diagnostics.

While not exclusively healthcare-focused, its health portfolio is one of the most forward-thinking, with a strong emphasis on early-stage innovation. Its proximity to the tech ecosystem offers a distinct advantage in healthtech convergence.

General Catalyst (Massachusetts, USA)

General Catalyst has grown into a notable player in healthcare VC, especially through its Health Assurance Fund. The firm is based in Cambridge, Massachusetts—home to some of the world’s top biotech and academic institutions.

General Catalyst emphasizes long-term partnerships with companies and health systems focused on modernizing care infrastructure – an approach that resonates with my own experience leading product strategy at Airbnb.

Lightspeed Venture Partners (California, USA)

Lightspeed has expanded its healthcare investments over recent years, with an emphasis on tech-enabled healthcare services and platforms. With a strong presence in Silicon Valley and additional offices in India, Israel, and China, it has a growing international footprint and a focus on scalable healthcare technologies.

Plug and Play Ventures (California, USA)

Plug and Play is both an investor and accelerator, offering startups access to a large network of corporate partners. Its health program, run from Silicon Valley, works closely with hospitals, insurers, and pharma companies. The firm’s international reach includes operations in Europe and Asia, helping its portfolio companies scale globally.

These firms represent a mix of sector specialists and broader VC firms with dedicated healthcare arms.

While the United States remains the dominant hub—especially in California, Massachusetts, and New York—several firms have expanded internationally to tap into new innovation centers in Europe, Asia, and Canada.

Fund Sizes and Performance of Health Care VC Firms

The scale of a venture capital firm’s fund and how it allocates capital are key indicators of its investment power and strategic direction.

In the healthcare sector, top VC firms vary widely in fund size, but all share a common goal: deploying capital into innovations that can transform patient care and generate strong returns.

Fund Size and Structure by Firm

OrbiMed manages one of the largest pools of dedicated healthcare capital globally, with funds ranging from early-stage venture to crossover and public equity.

In its most recent venture fund, OrbiMed is one of the largest healthcare investment firms globally, managing approximately $17 billion across public and private investments.

In October 2023, it raised over $4.3 billion across three new funds, giving it the capacity to participate in both early clinical investments and late-stage commercial opportunities.

New Enterprise Associates (NEA), while not exclusive to healthcare, has raised some of the largest VC funds in the industry. Its diversified model allows for large allocations to healthcare, especially for biotech and medtech.

In January 2023, NEA closed two funds totaling $6.2 billion, the largest in its history. Previous funds have also been among the largest in the industry, including a $3.6 billion fund closed in 2020.

Having deployed over $300 million in capital myself, I’ve seen how firms like NEA use this scale to support companies across multiple financing rounds and stages of growth.

Andreessen Horowitz (a16z) created a dedicated bio fund exceeding $1 billion. The firm focuses its capital on digital health, AI in life sciences, and computational biology. Its approach is to lead or co-lead rounds with the ability to follow on in later stages, using capital to scale companies with breakthrough potential.

Versant Ventures has structured its funds to support both new venture creation and external investments. In April 2021, the firm raised $950 million across three vehicles: a $560 million primary fund, a $140 million booster fund for early-stage performers, and a $250 million opportunity fund for later-stage rounds.

Its capital structure is tightly linked to its internal discovery engines, which incubate companies in-house before outside syndicates join.

Capital Deployment Priorities

Deployment strategies vary based on firm focus. Optum Ventures takes a stage-flexible approach but prioritizes companies that align with its broader healthcare delivery and payer ecosystem.

Much of its capital goes toward digital platforms and analytics tools that can be scaled within existing health systems.

Deerfield Management uses a hybrid model, blending venture and growth investments with significant allocation to therapeutics.

The firm also deploys capital through strategic initiatives like Deerfield Discovery and Development, designed to accelerate academic research into commercial-stage ventures. Its capital deployment emphasizes de-risked science and strong IP portfolios.

General Catalyst, through its Health Assurance Fund, takes a thematic approach—identifying macro-level problems in healthcare (e.g., access, affordability) and backing companies that aim to solve them. This strategy directs capital toward platform solutions, including tech-enabled primary care, EHR interoperability, and virtual-first care delivery.

Performance Metrics and Outlook

While private VC firms don’t always disclose full performance data, industry reports and LP statements indicate that top healthcare VC firms continue to outperform broader benchmarks, particularly in biotech and digital health exits. For example:

• NEA and OrbiMed have had multiple portfolio companies go public or be acquired in the past five years, with many exit values exceeding $500 million, including high-profile acquisitions such as ARMO, Loxo Oncology, and Acerta Pharma.
• Andreessen Horowitz has made high-profile early bets on companies using AI for drug discovery through its bio fund, though specific IRR performance is not publicly disclosed.
• Versant Ventures has a consistent track record of high multiple returns from internally incubated biotech firms, many of which go on to raise substantial follow-on rounds or secure pharma partnerships.

Despite cautious capital pacing in recent quarters, these firms remain well-capitalized and active. Dry powder levels are high across many of them, positioning them to take advantage of pricing corrections and to continue supporting top-performing portfolio companies.

In short, the top healthcare VC firms are not only raising large funds—they are also deploying capital with discipline and generating strong returns by focusing on well-defined niches and leveraging internal expertise.

Deal Flow and Trends Among Health Care VC Firms

The strength of a healthcare VC firm lies in the quality of its deal flow and the clarity of its investment criteria. Leading firms don’t just passively review opportunities — they actively shape the pipeline by building strong sourcing networks, nurturing repeat founders, and tracking emerging technologies. This section explores how top healthcare VC firms evaluate startups and how their investment theses are evolving in response to innovation and industry pressures.

How Top Firms Source Their Best Deals

Versant Ventures often generates its own deal flow through in-house incubation. The firm operates discovery engines in San Diego, Basel, and Vancouver, allowing it to build biotech companies from early research projects. This gives it a competitive edge in sourcing proprietary science and forming startups with baked-in scientific depth.

Andreessen Horowitz leans heavily on founder networks and technical communities, particularly in AI and computational biology. Many of its portfolio companies come from repeat founders or academic spinouts that align with the firm’s thesis around software-driven health innovation.

OrbiMed maintains one of the most robust global sourcing networks. With boots on the ground in the U.S., Asia, and Europe, the firm is able to identify promising companies across regulatory environments and healthcare systems. It often gets early access to cross-border deals and emerging biotech platforms.

Plug and Play Ventures, due to its accelerator model, sees high volumes of early-stage healthtech startups from its global programs. It filters deal flow through corporate partners (hospitals, insurers, pharma), giving the firm insights into what the market actually wants.

What Firms Are Looking for in 2025

Investment criteria have become more selective. Across leading firms, the most common priorities include:

• Validated science or data (especially for biotech and diagnostics)
• Scalability of platform (digital health, infrastructure tools)
• Experienced or repeat founders
• Clear reimbursement or regulatory path
• Strategic alignment with health system needs

Deerfield Management, for instance, tends to avoid preclinical bets unless the science is extremely de-risked. It focuses on companies with clear commercialization pathways, strong IP, and experienced leadership.

General Catalyst places high value on system-level change. It favors companies that align with its “health assurance” thesis — those building sustainable, tech-enabled care models that improve outcomes while reducing cost.

Evolving with the Industry

Top firms are adjusting their filters in response to macro and technological shifts. A few trends influencing deal flow in 2025:

• AI in drug discovery and clinical workflow tools is attracting heavy attention. Firms like a16z and Khosla Ventures are prioritizing startups that integrate AI in a way that adds clinical or operational value.
  
• Onshoring of biotech manufacturing and supply chains is shaping how firms like OrbiMed and Versant evaluate investment risk and scalability.
  
• Aging populations and chronic disease management are pushing firms like Optum Ventures to look for scalable care delivery platforms and data analytics solutions.
  
• Valuation discipline has returned. With market corrections in recent years, firms are now more cautious on pricing, and late-stage companies need stronger proof points to justify higher rounds.

Rather than casting wide nets, the best firms are refining their theses and going deeper within targeted verticals. This selective approach helps them maintain deal quality, back more resilient companies, and stay ahead of where healthcare innovation is heading.

Just as investors are refining theses within health care, similar patterns can be seen in other sectors. In areas like ed tech venture capital, agtech venture capital, and biotech venture capital, firms are narrowing their focus, forming strategic syndicates, and pursuing highly specialized deal flow.

Networks and Portfolios of Health Care VC Firms

In healthcare venture capital, strong networks often matter as much as capital. The most successful VC firms consistently leverage deep relationships across healthcare systems, academia, regulators, and industry to identify promising startups and help them scale.

These networks don’t just help firms find deals—they’re instrumental in helping portfolio companies navigate clinical development, regulatory approval, and commercial rollout.

How Networks Drive Deal Success

OrbiMed benefits from longstanding ties with pharmaceutical companies, academic labs, and public market investors. These relationships give it early access to cutting-edge science and make it a preferred co-investor for syndicates involving large crossover funds.

OrbiMed’s close ties with public markets also position it to support IPO-bound companies with strategic follow-on financing.

Versant Ventures taps into international academic institutions, particularly in Switzerland, Canada, and the U.S. Its discovery engines work hand-in-hand with local universities and research hospitals to incubate biotech startups from foundational research.

This allows the firm to build companies with well-vetted scientific backing and faster clinical readiness.

General Catalyst maintains close partnerships with health systems such as Intermountain Healthcare and Jefferson Health, among others. These relationships help the firm vet new care delivery models in real-world settings. Portfolio companies benefit by piloting solutions directly within clinical environments, accelerating both product validation and adoption.

Optum Ventures, as the venture arm of UnitedHealth Group, has unparalleled access to payers, providers, and claims data. This unique network allows its portfolio companies to integrate more quickly with health plans and clinical workflows—giving startups a clearer path to market.

Plug and Play Ventures operates one of the most expansive innovation networks globally. Through its accelerator partnerships with healthcare incumbents—ranging from pharma companies to hospital chains—it helps startups secure pilots, refine product-market fit, and find strategic acquirers.

Notable Portfolio Companies and How They Benefited

• Devoted Health (backed by Andreessen Horowitz and General Catalyst) –  A tech-enabled Medicare Advantage provider. The company has raised significant funding and grown rapidly, though details about health system partnerships are not publicly confirmed.
  
• Tempus (backed by NEA and OrbiMed) –  A precision medicine platform using AI and clinical data for cancer treatment. While OrbiMed’s involvement is not explicitly confirmed, the company has expanded rapidly through clinical trials and partnerships with academic medical centers.
  
• Lyra Health (backed by Optum Ventures and a16z) –  A mental health benefits platform. Optum Ventures provided key access to employer healthcare networks and claims infrastructure, helping Lyra scale enterprise adoption.
  
• Graphite Bio (backed by Versant Ventures) –  gene-editing startup spun out of academic research and incubated by Versant. Its scientific foundation and regulatory readiness benefited directly from Versant’s discovery engine and global support team.
  
• BrightInsight (backed by General Catalyst and Insight Partners) –  A regulated digital health platform for pharma and medtech. While specific details are not publicly confirmed, VC partnerships and board networks likely supported its expansion into the pharmaceutical client base.

These examples show how top VC firms don’t just write checks—they build ecosystems around their companies. Through curated introductions, regulatory guidance, and real-world pilots, they create leverage that increases the likelihood of clinical and commercial success.

Who Backs the Best Health Care VC Firms?

Behind every successful venture capital firm is a group of limited partners (LPs) who provide the capital that powers its investments. In healthcare VC, the composition of LPs reveals a great deal about a firm’s scale, strategy, and alignment with long-term innovation. Top firms tend to attract sophisticated institutional LPs, while others may have specialized backers aligned with their sector focus.

Institutional LPs Fueling Large Healthcare VC Firms

New Enterprise Associates (NEA) and OrbiMed raise funds with backing from a wide range of institutional LPs, including pension funds, university endowments, insurance companies, and foundations.

These investors are drawn by the firms’ long track records and ability to manage billion-dollar funds. Their presence signals confidence in the firm’s performance and provides stability across fund cycles.

Versant Ventures, though slightly smaller in fund size, also draws substantial institutional interest, particularly from endowments and international investors. Its cross-border presence and biotech specialization make it attractive to LPs seeking exposure to innovation outside the U.S.

Deerfield Management combines traditional LP capital with its own proprietary assets. This blended model gives the firm flexibility in capital deployment and alignment with long-term healthcare initiatives.

Deerfield also partners with philanthropic and academic institutions through special-purpose vehicles aimed at accelerating translational research.

Strategic LPs and Corporate Investors

Firms like Optum Ventures are backed by corporate capital—in this case, from UnitedHealth Group. As a strategic VC arm, its funding is internal, and its LP structure is singular.

However, this also means that its investments are closely aligned with the parent organization’s strategic goals. Startups that align with UnitedHealth’s vision can benefit from more than just funding—they gain integration opportunities and market access.

Plug and Play Ventures maintains a different model altogether. It is backed by a consortium of global corporations—pharmaceutical companies, hospital networks, and insurers—who participate in its accelerator programs. These LPs are not traditional capital providers in the VC sense, but they offer channel partnerships, pilot opportunities, and M&A pathways for portfolio companies.

Specialized and Thematic LP Structures

General Catalyst has raised thematic funds, such as its Health Assurance Fund, which appeals to LPs interested in long-term transformation of healthcare infrastructure.

These LPs are often aligned with mission-driven goals, including improved health outcomes, cost reduction, and digital transformation. This structure allows General Catalyst to build long-term alignment between investor capital and firm strategy.

Khosla Ventures, while broadly tech-focused, often attracts LPs looking for exposure to moonshot innovation. Its healthcare-related LP base tends to include high-net-worth individuals, family offices, and institutional funds with a high risk tolerance for disruptive healthtech plays.

Why LP Composition Matters

The makeup of a firm’s LPs impacts everything from fund size and investment timelines to portfolio risk appetite. Institutional LPs demand disciplined fund management and strong reporting.

Corporate LPs expect strategic synergies. And mission-driven LPs want to see tangible impact alongside financial returns.

For healthcare founders and professionals evaluating VC firms, understanding who funds them can offer valuable insight into how decisions are made, what kind of support is available, and whether a firm has the stability to follow through on long-term commitments.

What Makes a Top Healthcare VC Firm?

Top healthcare venture capital firms don’t just provide funding—they shape the direction of the industry. What separates the best from the rest is not just capital under management or headline-grabbing exits.

It’s the combination of strategic focus, operational discipline, and long-term partnerships that consistently turn promising startups into category leaders.

1. Strategic Clarity and Sector Focus

Leading firms define their investment themes with precision. Whether it’s biotech, digital health, AI in diagnostics, or healthcare infrastructure, top firms choose sectors where they have deep knowledge and can create outsized value. OrbiMed’s specialization in therapeutics and General Catalyst’s focus on health system modernization are strong examples of this.

2. Deep Relationships and Ecosystem Integration

Strong healthcare VC firms don’t operate in isolation. They build meaningful partnerships with hospitals, research institutions, pharma companies, and payers. This network strength helps firms like Optum Ventures and Versant Ventures accelerate clinical validation, regulatory navigation, and market access for their portfolio companies.

3. Selective, High-Quality Deal Flow

Rather than chasing trends, top firms cultivate focused, high-conviction deal pipelines. Firms like Andreessen Horowitz and Deerfield Management invest based on tightly defined criteria—founder quality, clinical proof, scalable tech, or regulatory clarity. Their discipline ensures that capital is directed toward startups with strong fundamentals and growth potential.

4. Support Beyond the Check

Elite firms are hands-on, offering operational guidance, strategic hiring, product-market fit support, and even regulatory navigation. Many also provide structured post-investment platforms—such as Plug and Play’s accelerator model or Versant’s in-house incubation. Founders backed by these firms often cite the depth of support as a key advantage.

5. Long-Term Alignment with Limited Partners

Finally, top healthcare VC firms are backed by long-term, aligned LPs—whether institutional, strategic, or mission-driven. This backing gives firms stability and allows them to stay focused on big, complex healthcare problems that may take years to solve. Firms like NEA and OrbiMed, with long LP relationships and repeat fund cycles, exemplify this stability.

Frequently Asked Questions

What types of companies do health care VC firms usually invest in?

Most health care VC firms invest in startups that focus on biotechnology, digital health, medical devices, diagnostics, or health care services. The stage of the company can range from early product development to late-stage commercialization, depending on the firm’s strategy.

How can a startup get noticed by a health care VC firm?

Startups often gain attention through referrals, accelerator programs, or by having a strong founding team with experience in health care or technology. Having clinical validation, a clear business model, or early traction can also help.

What’s the difference between generalist VCs and health care-focused VCs?

Generalist VCs invest across many industries, while health care-focused VCs specialize in health-related sectors. Specialized firms tend to have deeper networks and more experience navigating regulatory, scientific, or clinical challenges.

How do health care VC firms decide which areas to focus on?

Firms usually develop investment themes based on market needs, emerging technologies, and the expertise of their team. Some specialize in specific areas like oncology or mental health, while others follow broader trends like personalized medicine or AI-driven diagnostics.

How involved are health care VC firms after they invest?

Involvement varies, but leading firms often take an active role. This can include joining the board, helping with strategic decisions, making introductions to partners, or guiding clinical and regulatory strategy.

Conclusion

Health care venture capital firms play a major role in advancing medical innovation and shaping how care is delivered. By backing startups that bring new ideas and technologies to market, these firms help drive progress across biotech, digital health, and more. Understanding who they are, how they invest, and what makes them successful can offer valuable insight for founders, investors, and professionals in the space.

As global health challenges grow more complex, the influence of these firms will only become more important. Their ability to identify transformative ideas, support specialized teams, and bring new solutions to patients will continue to shape the future of medicine, care delivery, and health system innovation.

Learn more about sector-focused venture capital.